RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, England, March 18, 2024 /PRNewswire/ -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic solid tumors.
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...
Fennec Pharmaceuticals` Pedmarqsi (sodium thiosulfate) Receives Approval in Europe
RESEARCH TRIANGLE PARK, N.C., June 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced Pedmarqsi™– known as PEDMARK® in the U.S. – was granted marketing authorization by the European Commission. Pedmarqsi is the first and only approved therapy in the EU for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumors. Further, Pedmarqsi was granted the marketing authorization under the paediatric-use marketing authorization (PUMA) which includes 8 years plus 2 years of data and market protection.
RESEARCH TRIANGLE PARK, N.C., June 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced Pedmarqsi„¢“...
Fennec Pharmaceuticals` Pedmarqsi (sodium thiosulfate) Receives Approval in the Europe
Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsiâ„¢ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
The FDA has granted orphan drug exclusivity to sodium thiosulfate (Pedmark) injection, which is indicated to reduce the risk of platinum-induced ototoxicity in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors, according to an announcement from Fennec Pharmaceuticals.1
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
FDA Confirms Paragraph IV Patent Litigation for Sodium Thiosulfate Intravenous Injection